# A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period

> **NCT07733089** · PHASE1 · RECRUITING · sponsor: **Zealand Pharma** · enrollment: 32 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** ZP9830
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07733089
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-22
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-07-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733089, "A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07733089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*